1. Home
  2. DIBS vs NBTX Comparison

DIBS vs NBTX Comparison

Compare DIBS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 1stdibs.com Inc.

DIBS

1stdibs.com Inc.

HOLD

Current Price

$4.21

Market Cap

135.8M

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

N/A

Current Price

$35.28

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DIBS
NBTX
Founded
2000
2003
Country
United States
France
Employees
266
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.8M
2.0B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
DIBS
NBTX
Price
$4.21
$35.28
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$7.00
$36.00
AVG Volume (30 Days)
86.1K
135.4K
Earning Date
05-08-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
22.45
N/A
EPS
N/A
N/A
Revenue
$89,620,000.00
N/A
Revenue This Year
$3.12
$58.17
Revenue Next Year
$1.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.54
N/A
52 Week Low
$2.50
$14.30
52 Week High
$6.62
$57.14

Technical Indicators

Market Signals
Indicator
DIBS
NBTX
Relative Strength Index (RSI) 43.04 N/A
Support Level $4.03 N/A
Resistance Level $4.90 N/A
Average True Range (ATR) 0.25 0.00
MACD -0.04 0.00
Stochastic Oscillator 37.98 0.00

Price Performance

Historical Comparison
DIBS
NBTX

About DIBS 1stdibs.com Inc.

1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: